[go: up one dir, main page]

AR124985A1 - Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona - Google Patents

Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona

Info

Publication number
AR124985A1
AR124985A1 ARP220100427A ARP220100427A AR124985A1 AR 124985 A1 AR124985 A1 AR 124985A1 AR P220100427 A ARP220100427 A AR P220100427A AR P220100427 A ARP220100427 A AR P220100427A AR 124985 A1 AR124985 A1 AR 124985A1
Authority
AR
Argentina
Prior art keywords
acid
cyp11a1
inhibitor
piran
ona
Prior art date
Application number
ARP220100427A
Other languages
English (en)
Inventor
Oskari Karjalainen
Mikko Mkel
Mihaela Pop
Petteri Rummakko
Anna Shevchenko
Kari Sinervo
Eija Tiainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR124985A1 publication Critical patent/AR124985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a sales nuevas, particularmente sales cristalinas, de 2-(isoindolin-2-ilmetil)-5-((1-(metilsulfonil)piperidin-4-il)metoxi)-4H-piran-4-ona (I) que son particularmente adecuadas para su uso en la fabricación de composiciones farmacéuticas. Además, la invención se refiere a composiciones farmacéuticas que comprenden dichas sales nuevas. El compuesto (I) es un inhibidor selectivo de la enzima CYP11A1 y es útil en el tratamiento de cánceres regulados por hormonas, tal como el cáncer de próstata y el cáncer de mama. Reivindicación 1: Una sal de 2-(isoindolin-2-ilmetil)-5-((1-(metilsulfonil)piperidin-4-il)metoxi)-4H-piran-4-ona (I) con un ácido seleccionado del grupo caracterizada porque consiste en ácido p-toluenosulfónico, ácido 2-naftalenosulfónico, ácido 1,5-naftalenodisulfónico, ácido bromhídrico, ácido nítrico, ácido bencenosulfónico, ácido clorhídrico, ácido maleico, ácido 1,2-etanodisulfónico, ácido oxálico, ácido etanosulfónico, ácido sulfúrico y ácido metanosulfónico.
ARP220100427A 2021-03-01 2022-02-25 Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona AR124985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20215217 2021-03-01

Publications (1)

Publication Number Publication Date
AR124985A1 true AR124985A1 (es) 2023-05-24

Family

ID=80685169

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100427A AR124985A1 (es) 2021-03-01 2022-02-25 Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona

Country Status (16)

Country Link
US (1) US20240158377A1 (es)
EP (1) EP4301750A1 (es)
JP (1) JP2024511297A (es)
KR (1) KR20230165775A (es)
CN (1) CN117242069A (es)
AR (1) AR124985A1 (es)
AU (1) AU2022230234A1 (es)
BR (1) BR112023017416A2 (es)
CA (1) CA3210592A1 (es)
CL (1) CL2023002588A1 (es)
CO (1) CO2023011532A2 (es)
IL (1) IL305517A (es)
MX (1) MX2023010268A (es)
PE (1) PE20240084A1 (es)
TW (1) TW202302578A (es)
WO (1) WO2022184978A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008838A (es) * 2022-01-20 2024-09-23 Orion Corp Composicion farmaceutica de un inhibidor de cyp11a1.
WO2025017072A1 (en) * 2023-07-19 2025-01-23 Orion Corporation Stable pharmaceutical compositions of a cyp11a1 inhibitor
KR20250078725A (ko) 2023-11-24 2025-06-04 주식회사 엘지에너지솔루션 배터리 진단 장치 및 배터리 진단 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
AR110412A1 (es) 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Also Published As

Publication number Publication date
IL305517A (en) 2023-10-01
AU2022230234A1 (en) 2023-09-07
CA3210592A1 (en) 2022-09-09
JP2024511297A (ja) 2024-03-13
WO2022184978A1 (en) 2022-09-09
EP4301750A1 (en) 2024-01-10
CO2023011532A2 (es) 2023-11-20
CL2023002588A1 (es) 2024-02-02
MX2023010268A (es) 2023-11-14
PE20240084A1 (es) 2024-01-16
KR20230165775A (ko) 2023-12-05
US20240158377A1 (en) 2024-05-16
CN117242069A (zh) 2023-12-15
TW202302578A (zh) 2023-01-16
BR112023017416A2 (pt) 2023-09-26

Similar Documents

Publication Publication Date Title
AR124985A1 (es) Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
PE20241296A1 (es) Inhibidores de fgfr y metodos de fabricacion y uso de los mismos
DOP2019000087A (es) Compuestos químicos
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
BR112023000350A2 (pt) Sais e formas de um inibidor de wee1
PE20141069A1 (es) Marcadores de enfermedad tromboembolica
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CR20130102A (es) Imidazopiridazinas sustituidas
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
CO2018009124A2 (es) Análogos de cannabidiol biológicamente activos
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
BR112016028219A2 (pt) composto, método de tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, método de tratamento ou prevenção de leucemia, câncer de pulmão de não pequenas células, carcinoma hepatocelular, ou glioblastomas em um indivíduo, método de tratamento de uma doença ou distúrbio em um indivíduo, composição farmacêutica e processo para obtenção de um composto de fórmula (i)
AR056518A1 (es) Polimorfos de la sal benzoato de 2-[[6-[(3r)-3-amino-1-piperidinil]3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil] metil] benzoanitrilo (compuesto 1) y metodos para usarlos
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP099465A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y métodos
DOP2011000067A (es) Derivados de picolinamida como inhibidores de cinasa
NI201000175A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
DOP2010000309A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
CU23784B7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4